The Latest Cardiac and Vascular News
Company expands portfolio of solutions with groundbreaking insertable cardiac monitor system MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced a sales agent […]
MARLBOROUGH, Mass., July 29, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an operational1 basis and (28.7) percent on an organic2 basis, all compared to the prior year period. The company reported a […]
New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Experience […]
First ICM device with remote programming paired with dual-stage arrhythmia detection algorithm MARLBOROUGH, Mass., June 29, 2020 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device implanted in patients to detect arrhythmias associated with […]
Tool provides electrophysiologists with first-ever local measurement and visualization of tissue response to radiofrequency ablation MARLBOROUGH, Mass., June 1, 2020 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ […]
Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy […]
MARLBOROUGH, Mass., April 29, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an operational1 basis and a decline of 2.9 percent on an organic2 basis, all compared to the prior year period. The […]
SAN CARLOS, Calif., April 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing which has been filed today with the Securities and Exchange Commission on Form 8-K. BioCardia, Inc. […]
MARLBOROUGH, Mass., Jan. 14, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company’s guidance range of 13 to 15 percent; approximately 14.1 percent on […]
Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical […]
